Evidence map›Paper›PMID 26942004›Full record

ArticleJournal of ophthalmology2016

Nonlethal Levels of Zeaxanthin Inhibit Cell Migration, Invasion, and Secretion of MMP-2 via NF-κB Pathway in Cultured Human Uveal Melanoma Cells.

Ming-Chao Bi, Nicole Hose, Cai-Lian Xu, Chen Zhang, Jodi Sassoon, E Song

Open access · goldAbstract read
In one paragraph

Article in Journal of ophthalmology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Zeaxanthin-Rich Extract from SuperfoodMolecules (Basel, Switzerland) · 2021
    Article
  6. Review
  7. Review
  8. Article
  9. The biology of uveal melanoma.Cancer metastasis reviews · 2017
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Ming-Chao BiDepartment of Ophthalmology, The First Hospital of Jilin University, Changchun 130021, China; Tissue Culture Center, The New York Eye and Ear Infirmary of Mount Sinai, New York, NY 10003, USA.
Nicole HoseFordham University, New York, NY 10023, USA.
Cai-Lian XuDepartment of Ophthalmology, The First Hospital of Jilin University, Changchun 130021, China.
Chen ZhangShanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
Jodi SassoonTissue Culture Center, The New York Eye and Ear Infirmary of Mount Sinai, New York, NY 10003, USA.
E SongDepartment of Ophthalmology, The First Hospital of Jilin University, Changchun 130021, China; Lixiang Eye Hospital of Soochow University, Suzhou 215021, China.
First Hospital of Jilin University · CNFordham University · USJilin University · CNNew York Eye and Ear Infirmary · USTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Zeaxanthin at nonlethal dosages (3-10 μM) significantly inhibited the cell migration of cultured uveal melanoma cells (C918 cell line) as determined by wound healing assay and Boyden chamber assay. Matrigel invasion assay showed that cell invasion of uveal melanoma cells could be significantly inhibited by zeaxanthin. Secretion of MMP-2 by melanoma cells was significantly inhibited by zeaxanthin in a dose-dependent manner as measured by ELISA kit. Zeaxanthin also significantly inhibited the NF-κB levels in nuclear extracts of the UM cells, which is the upstream of the MMP-2 secretion. These results suggest that zeaxanthin might be a potentially therapeutic approach in the prevention of metastasis in uveal melanoma.

Identifiers

PMID26942004
PMCPMC4749803
OpenAlexW2293780619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.